International CML Foundation

Home
United Kingdom
Bexhill-on-Sea
International CML Foundation

Website

Improving outcomes for patients with CML globally. The International CML Foundation (iCMLf) is on a mission to improve outcomes for patients with CML, globally.

Founded by a dedicated group of hematologists, we are committed to ensuring every patient with CML, no matter where they are in the world, receives the best possible care. We foster international collaboration to elevate knowledge, enhance diagnostics, and drive ground-breaking research. As a charitable foundation with a global reach, we strive to empower physicians, researchers, patients and caregivers alike, in the collective pursuit of a cure. Join us and contribute to a world where a cure for CML is not just a hope, but a reality.

04/11/2026

What happens when guidelines meet the realities of everyday practice?

The third iCMLf Saudi Arabian Regional Discussion Group looked at two closely linked themes: quality of life for people living with CML, and managing CML in young adults.

From managing treatment intolerance to supporting younger patients with adherence, TFR and pregnancy, the discussions emphasised the need to adapt CML management to each patient’s comorbidities, priorities and circumstances.

📄 Read the report now: https://buff.ly/1z4ueNk

03/11/2026

It’s been three weeks since the John Goldman Fun Run in Gothenburg, and we still can’t get over it! Around 50 runners and walkers came together for a fantastic morning, raising a record US$3,333 for the Foundation’s mission to improve outcomes for people living with CML 💜

A heartfelt thank you to François-Xavier Mahon for capturing the spirit of the Fun Run in this video! 📹

28/10/2026

Missed our iCMLf Conversation on the highlights of ESH-iCMLf 28th Annual John Goldman Conference on CML: Biology and Therapy?

The recording is now available.

In this session, Professor Daniela Krause and Professor Jorge Cortes shared their expert summaries of key sessions and abstracts from the conference, covering both biological and clinical aspects, as well as answering questions from the audience in a live Q&A.

Watch the recording here: https://buff.ly/xIatet2

27/10/2026

Did you miss our latest Regional Discussion Group for Africa, held on 21 October? The recordings are now available in both English and French. Catch up on the discussions and revisit key takeaways from the session.

Watch the recordings here 👇️
▶️ CML and fertility, pregnancy and lactation: https://buff.ly/S6SbjJK
▶️ ELN 2025 recommendations - Key changes that will impact CML treatment in Africa: https://buff.ly/pYWIJwI

22/10/2026

Here is our selection of CML papers for September, curated this month by Professor Tim Hughes. The publications are being shared a little later than usual this month due to the recent ESH-iCMLf 28th Annual John Goldman Conference on CML: Biology and Therapy.

1️⃣ “First line asciminib in chronic myeloid leukemia: a quest for the ‘Holy Grail’ of tolerability”, Rea D. Haematologica, September 2026, (epub ahead of print)
Open access publication
https://buff.ly/prQS3yo

2️⃣ “Mitochondrial DNA mutations are associated with impaired oxidative phosphorylation and enhanced imatinib response”, Pagani IS et al. Hemasphere, September 2026
Open access publication
https://buff.ly/wwglW52

3️⃣ “Imatinib treatment and vaccination in an infant with chronic myeloid leukemia diagnosed when 40 days old”, Dogru O., et al., Blood Global Hematology, September 2026
Open access publication
https://buff.ly/Vil9zxw

4️⃣ “Cost effectiveness analysis of asciminib in patients with chronic phase CML previously treated with 2 or more TKIs in Colombia”, Ceballos M et al. Value Health Reg Issues, September 2026 (epub ahead of print)
Open access publication
https://buff.ly/pRHKB3e

📖 Explore the full list of papers on our website: https://buff.ly/0GGW5yu

21/10/2026

📌 Registration now open!

Join us for the third and final session of the 2026 iCMLf Regional Discussion Groups for physicians in Africa, taking place on Wednesday, 18 November.

Faculty:
🔹 Professor Jerry Radich (USA)
🔹 Dr Delphine Rea (France)
👉️ Additional faculty to be announced

Event details:
💻 Online
⏰ Accra/Dakar 17:00 · Abuja 18:00 · Khartoum/Beira 19:00 · Addis Ababa/Moshi/Nairobi 20:00
🗣️ Simultaneous interpretation available in French

Places are limited, so register today!👇️
https://buff.ly/VaoQ6PV

20/10/2026

🔍 Highlights from the ESH-iCMLf 28th Annual John Goldman Conference on Chronic myeloid leukemia: Biology and Therapy - Scientific Session: Treatment-free remission.

We’re pleased to share the fifth iCMLf summary from . Chaired by Delphine Rea, this session explored opportunities to improve TFR success through better patient selection, repeated discontinuation attempts and gradual TKI dose reduction.

📄 Read the full session summary and key takeaways: https://buff.ly/3g4qh4J

19/10/2026

🔊 We're live today!

This is your last chance to join the iCMLf Conversation: Post-conference highlights from ESHCML2026. Hear directly from Professors Daniela Krause and Jorge Cortes as they share their personal perspectives and key biological and clinical highlights from the meeting.

Don't miss this opportunity to catch up on the latest developments in CML and ask your questions during the live Q&A.

Register now: https://buff.ly/i6Pgo2K

16/10/2026

Heading to New Orleans for ASH? Join us the day before!

New therapies, new formulations and better testing are changing what is possible in CML. The real question is how quickly these advances reach patients in every setting, including where resources are limited.

Join physicians, patient advocates and industry partners at the iCMLf Forum for an open discussion of the challenges and opportunities ahead.

🔬 iCMLf Forum 2026: Promise to Practice
📅 Friday 11th December 2026, 12-2:30pm CT
📍 SpringHill Suites New Orleans Warehouse District, New Orleans

Register now: https://buff.ly/kreBsuq

15/10/2026

🔍 Highlights from the ESH-iCMLf 28th Annual John Goldman Conference on Chronic myeloid leukemia: Biology and Therapy - Scientific Session: Clinical trials.

We're pleased to share the third iCMLf summary from . Chaired by Ehab Atallah, this session explored the evolving landscape of CML treatment, highlighting emerging tyrosine kinase inhibitors (TKIs), new clinical trial results and strategies to improve long-term patient outcomes.

📄 Read the full session summary and key takeaways: https://buff.ly/425f2Gg

Address

Bexhill

Website

http://www.cml-foundation.org/

Alerts

Be the first to know and let us send you an email when International CML Foundation posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.